Memry Corp

Memry — NOBLE Investor Conference August 2007

30 slides from Memry's conference presentation, Aug 20, 2007

  1. Slide 1: Memry NOBLE Investor Conference August 2007

    MEMRY NOBLE Investor Conference August 2007

  2. Slide 2: Forward-looking statements

    This presentation contains certain forward-looking statements which involve known and unknown risks, uncertainties or other factors not under the Company’s control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance, or

  3. Slide 3: Compelling Value Proposition

    Compelling Value Proposition Innovative, Strategic Technology Solutions Large and Growing Medical Device Market Strong Growing Pipeline Strong Balance Sheet Strong Cash Generator Building Momentum Trading Near Book Value

  4. Slide 4: Enabling minimally invasive and targeted therapies for the medical industry

    “Enabling minimally invasive and targeted therapies for the medical industry”

  5. Slide 5: Materials & Processes Enabling Properties (Metals)

    Materials & Processes Enabling Properties Superelastic & Shape Kink resistance Memory Nitinol Alloys Crush resistance Ability to recover large Wire & Tube Drawing deformation Laser Cutting Thermal Recovery Stent Manufacturing Confined Access & Delivery Wire Forming i Surface Finishing Low Constant U

  6. Slide 6: Materials & Processes Enabling Properties (Polymers)

    Materials & Processes Enabling Properties Custom Co-Extruded Multi Layer Polymer Components Multi Lumen Polyurethanes Coil and Braid Reinforcement Myers Thin Wall Polyesters : Fluoropolymers Jacketi ng Polyimides Radiopacity Tipping & Forming Tapering Grinding Braiding & Coiling Catheter-based Minim

  7. Slide 7: Medical device market by segment

    2005 MOrthopaedics lsurgery/Endosurgery Cardiovascular/Thoracic ® Surgical Devices & Instruments Monitoring/Imaging i Electrosurgical/Auxiliary Equipment @ Robotics (Source: BCC Research, June 2006)

  8. Slide 8: Improving Quality of Healthcare

    Improving Quality of Healthcare Aging Population Stringent Regulatory Environment Competition & Speed to Market Cost Containment Product Innovation & Technology Mergers & Acquisitions Globalization Vendor Base Consolidation

  9. Slide 9: Device OEMs want to focus on R&D, Technology, Sales & Marketing

    Device OEMs want to focus on R&D, Technology, Sales & Marketing, Distribution and Regulatory Issues Device companies outsource for a variety of reasons Reduce operating costs Expand their portfolio of capabilities Simplify supply chain logistics Reduce capital expenditures Larger, full-service suppl

  10. Slide 10: Full Suite of Capabilities

    Full Suite of Capabilities Supply Chain Management Technology Leadership Rapid Turnaround Quality & Competitive Pricing Device Application Knowledge Globalization

  11. Slide 11: Device value chain

    Finished Device Subassemblies & Assemblies Parts & Components ‘Semi-Finished Materials Raw Materials Metals Polymers Device Compan’ Device Company Stent grafts, surgical instruments, etc. eters, balloons, delivery sysi te Value Added Operations Value Added Operations Taser, grinding, EP, coiling, as

  12. Slide 12: Revenue by market and product

    P: : 57% li Vascular/Radiology EndoSurgery Coronary & EP MUrology/OBGYN Others Orthopaedics 27% Stents & Stent Grafts Catheters Endosurgical Instruments Bi Guidewires Others Embolic Protection Memry Corp., Estimated

  13. Slide 13: Markets served

    Neurology ® Ophthalmology Coronary & EP Vasfular/Radigiogy ow Endosurgery ; @ i Uroldgy/OBGyn re) | | 7 \ | Pp Pithopaedics \ | {

  14. Slide 14: Materials, Processes & Product Integration

    Materials, Processes & Product Integration High-end Processing Technologies Passive and Biointeractive Medical Polymers & Biomaterials Surface Modification & Finishing Technologies Integration Technologies Critical to Complete Product capability Vv Market Leadership & Recognition as Leading Provider

  15. Slide 15: Laser capability upgrade

    Laser capability upgrade Introduction of V2 ultra small diameter nitinol tubing Addition of plasma welding capability Launch of new product line, Putnam Plastics Plus Enhanced capability of guidewire finishing and coating

  16. Slide 16: ISO 13485:2003 Certification for all plants

    ISO 13485:2003 Certification for all plants (completed) Electropolishing capability and facility upgrade Addition of insert molding line for catheter manufacturing Addition of high volume hydrophilic coating line for guidewires Implementation fast turnaround tubing line

  17. Slide 17: Management team

    Robert Belcher, Chief Executive Officer Dean Tulumaris, President & Chief Operating Officer Richard Sowerby, Chief Financial Officer & Treasurer Philippe Poncet, Vice President Business Development Marcy Macdonald, Vice President Human Resources

  18. Slide 18: Fiscal year and nine months financial summary

    Fiscal Year Nine Months Ended 2005 A 2006 A 3/31/06A 3/31/07 A Revenue $45.0M $52.6M $39.3M $38.5M Gross Profit $17.9M $20.4M $15.6M $12.7M Gross Margin % 40% 39% 40% 33% Net Income $2.7M b) $2.7M a) $1.8M a)b) $0.3M a)b) Diluted EPS $0.10 $0.09 $0.06 $0.01 a) Includes $1.1M of CEO retirement charge

  19. Slide 19: Revenue Growth

    Revenue Growth (in millions) $34.4 $34.5 2000 2001 A 2002 2003 A 2004 A 2005 A 2006A 2007 P Fiscal Year

  20. Slide 20: Nitinol Segment Quarterly Revenue

    Nitinol Segment Quarterly Revenue (in thousands) Q105A 205A Q305A 405A Q10GA 206A Q306A 406A Q107A 207A Q307A aQso7P

  21. Slide 21: Polymer Segment Quarterly Revenue

    Polymer Segment Quarterly Revenue (in thousands) Q105A Q205A 305A Q405A Q106A QZ06A Q306A Q406A Q107A Q207A Q307A Q407P

  22. Slide 22: Invest in areas to generate revenue growth

    Invest in areas to generate revenue growth Development Projects New Technologies Sales & Marketing Look for cost improvement opportunities Insurance SEC, Legal Chemical Costs Achieve process efficiencies

  23. Slide 23: R&D Investment

    R&D Investment (in millions) ao 1.9 2.0 2004 A* 2005 A* 2006 A R&D Exp @R&D COGS * Putnam Plastics acquired in November 2004.

  24. Slide 24: R&D Revenue

    R&D Revenue (in millions) 2004 A* 2005 A* 2006 A 2007 P 4# R&D Revenue Total R&D Investment * Putnam Plastics acquired in November 2004.

  25. Slide 25: R&D Projects

    R&D Projects Metals @ Plastics

  26. Slide 26: Balance sheet March 2007

    March 2007A Current Assets $21.3 Property, Plant & Equipment E 8.9 Goodwill & Other Intangibles Other Assets Total Assets Current Liabilities Notes Payable, less current maturities Non-current Liabilities Stockholders Equity Total Liabilities and Stockholders Equity Total Debt

  27. Slide 27: EBITDA and Adjusted EBITDA definitions

    In this presentation, the Company refers to EBITDA and Adjusted EBITDA, financial measures that are not recognized under accounting principles generally accepted in the United States of America (“GAAP”). The Company defines EBITDA as earnings before income taxes, interest expense, net, depreciation

  28. Slide 28: EBITDA reconciliation, nine months ended

    Nine Months Ended 03/31/06A 03/31/07. Revenue $39.3 $38.5 Net Income $1.8 $0.3 + Income Taxes Ay d 1.1 0.1 + Interest Expense, Net 1.0 : 0.8 0.6 + Depreciation 19 5 1.6 1.7 + Amortization (a) 0.6 k 0.5 0.5 EBITDA $7.9 $3.2 + Incremental Litigation and Professional Fees (b) 04 0.2 + CEO Retirement (c

  29. Slide 29: EBITDA reconciliation footnotes

    a) Amortization excludes the amortization of deferred financing costs, which is included in interest expense, net. b) The Company incurred incremental fees for litigation and professional fees for litigation defense and the voluntary implementation of Sarbanes-Oxley Section 404 compliance. c) Effect

  30. Slide 30: Compelling Value Proposition

    Compelling Value Proposition Innovative, Strategic Technology Solutions Large and Growing Medical Device Market Strong Growing Pipeline Strong Balance Sheet Strong Cash Generator Building Momentum Trading Near Book Value

Memry — NOBLE Investor Conference August 2007 on 6ix